Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Change in Acquisitions & Divestments for 10 consecutive years, with $94.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 50.76% year-over-year to $94.3 million, compared with a TTM value of $371.7 million through Dec 2025, up 51.13%, and an annual FY2025 reading of $371.7 million, up 51.13% over the prior year.
  • Change in Acquisitions & Divestments was $94.3 million for Q4 2025 at Spyre Therapeutics, down from $99.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $106.9 million in Q2 2025 and bottomed at $3.2 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $45.5 million, with a median of $32.1 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 87.0% in 2023, then skyrocketed 1680.8% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $22.9 million in 2021, then fell by 19.26% to $18.5 million in 2022, then increased by 2.16% to $18.9 million in 2023, then soared by 230.94% to $62.5 million in 2024, then soared by 50.76% to $94.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for SYRE at $94.3 million in Q4 2025, $99.2 million in Q3 2025, and $106.9 million in Q2 2025.